drugset / Trial / NCT05723549

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

NCT05723549

Phase 1 Completed 20 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized, open-label, single-dose parallel study to evaluate the pharmacokinetics, safety and tolerability of HCP1803 in healthy male volunteers.

Timeline

Start
2023-02-02
Primary completion
2023-03-20
Completion
2023-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1803-3 Unknown
Comparator HCP1904-1 Unknown
Comparator RLD2002 Unknown

Indications

No indication recorded.